Jr. Macdonald et Dg. Pegg, EXTRAVASATION INJURY POTENTIAL OF CI-980, A NOVEL SYNTHETIC MITOTIC INHIBITOR, Cancer chemotherapy and pharmacology, 32(5), 1993, pp. 365-367
Severe soft-tissue ulceration is known to result from inadvertent extr
avasation of a number of anticancer drugs, including tubulin-binding v
inca alkaloids, during intravenous administration. CI-980 is a novel a
nticancer drug candidate that also inhibits mitosis by binding to tubu
lin. Intradermal administration of CI-980 to mice at doses of 0.02 and
0.05 mg produced ulcerative lesions in 3/5 and 2/5 animals, respectiv
ely, that were significantly smaller than those produced in all animal
s at vinblastine doses of 0.05 and 0.1 mg. Ulcerative lesions resultin
g from CI-980 treatment were also less persistent, resolving in 2-8 da
ys versus 7-16 days following vinblastine administration. As based on
the common dose of 0.05 mg, CI-980 appears to have significantly less
vesicant activity than vinblastine.